natgillin/translations-raw huggingface dataset:
Organklasse
49 System Organ
beregnes fra de foreliggende data) epidermal nekrolyse (potentielt livstruende) Knogler, led, muskler og bindevæv
Petechiae Erythema multiforme Erythema nodosum Stevens- Johnson syndrome (potentially life- threatening) Toxic epidermal necrolysis (potentially life- threatening)
Det er indberettet, at en overdosis på 12 g har medført lette toksiske symptomer.
50 An overdose of 12 g has been reported to lead to mild symptoms of toxicity.
52 * Ikke- artsrelaterede breakpoints er primært blevet bestemt på grundlag af PK/ PD- data, og er uafhængige af fordelingerne af MIC for specifikke arter.
1 Staphylococcus spp. - breakpoints for ciprofloxacin relate to high dose therapy. * Non-species-related breakpoints have been determined mainly on the basis of PK/ PD data and are independent of MIC distributions of specific species.
Yersinia pestis Anaerobe mikroorganismer Mobiluncus Andre mikroorganismer Chlamydia trachomatis ($) Chlamydia pneumoniae ($) Mycoplasma hominis ($) Mycoplasma pneumoniae ($) ARTER, HVOR ERHVERVET RESISTENS KAN VÆRE ET PROBLEM Aerobe grampositive mikroorganismer Enterococcus faecalis ($) Staphylococcus spp. * (2) Aerobe gramnegative mikroorganismer Acinetobacter baumannii+ Burkholderia cepacia+ * Campylobacter spp. + * Citrobacter freundii * Enterobacter aerogenes Enterobacter cloacae * Escherichia coli * Klebsiella oxytoca Klebsiella pneumoniae * Morganella morganii * Neisseria gonorrhoeae * Proteus mirabilis * Proteus vulgaris * Providencia spp.
Yersinia pestis Anaerobic micro-organisms Mobiluncus Other micro-organisms Chlamydia trachomatis ($) Chlamydia pneumoniae ($) Mycoplasma hominis ($) Mycoplasma pneumoniae ($) SPECIES FOR WHICH ACQUIRED RESISTANCE MAY BE A PROBLEM Aerobic Gram-positive micro-organisms Enterococcus faecalis ($) Staphylococcus spp. *(2) Aerobic Gram-negative micro-organisms Acinetobacter baumannii+ Burkholderia cepacia+* Campylobacter spp. +* Citrobacter freundii* Enterobacter aerogenes Enterobacter cloacae* Escherichia coli* Klebsiella oxytoca
Propionibacterium acnes ORGANISMER MED NATURLIG RESISTENS Aerobe grampositive mikroorganismer Actinomyces
Propionibacterium acnes INHERENTLY RESISTANT ORGANISMS Aerobic Gram-positive micro-organisms Actinomyces Enteroccus faecium Listeria monocytogenes Aerobic Gram-negative micro-organisms Stenotrophomonas maltophilia Anaerobic micro-organisms Excepted as listed above Other micro-organisms Mycoplasma genitalium Ureaplasma urealitycum * Clinical efficacy has been demonstrated for susceptible isolates in approved clinical indications + Resistance rate ≥ 50% in one or more EU countries ($):
Den maksimale. serumkoncentration nås efter 1- 2 timer.
Following oral administration of single doses of 250 mg, 500 mg, and 750 mg of ciprofloxacin tablets, ciprofloxacin is absorbed rapidly and extensively, mainly from the small intestine, reaching maximum serum concentrations 1-2 hours later.
Ciprofloxacin har en lav proteinbinding (20- 30%).
53 Protein binding of ciprofloxacin is low (20-30%).
55 Ciprofloxacin er kendt for at være en moderat hæmmer af CYP 450 1A2- iso- enzymer.
Ciprofloxacin is known to be a moderate inhibitor of the CYP 450 1A2 iso-enzymes.
Udskillelse af ciprofloxacin (% af dosis) Oral indgift
Excretion of ciprofloxacin (% of dose) Oral Administration
Data om fotomutagenicitet/ fotocarcinogenicitet viser en svag fotomutagen eller fototumorigen virkning af ciprofloxacin in vitro og i dyreforsøg.
54 phototumorigenic effect of ciprofloxacin in-vitro and in animal experiments.
Ciprofloxacin Bayer og tilhørende navne (se bilag I) 500 mg filmovertrukne tabletter [Se bilag I – Udfyldes nationalt]
Ciprofloxacin Bayer and associated names (see Annex I) 500 mg film-coated tablets [See Annex I - To be completed nationally]
4. 4 og 5. 1).
Ciprofloxacin Bayer 500 mg film-coated tablets are indicated for the treatment of the following infections (see sections 4.4 and 5.1).
58 • Infektioner i hud og bløddele forårsaget af gramnegative bakterier
• Infections of the skin and soft tissue caused by Gram-negative bacteria
• Malign ekstern otitis
57 • Malignant external otitis
500 mg som éngangsdosis
59 Indications
profylakse efter eksponering og kurativ behandling til patienter, som kan behandles oralt, når det er klinisk passende.
Inhalation anthrax post-exposure prophylaxis and curative treatment for persons able to receive treatment by oral route when clinically appropriate.
dagligt, maksimalt 500 mg pr. dosis.
10 mg/ kg body weight twice daily to 15 mg/ kg body weight twice daily with a maximum of 500 mg per dose.
af eksponering for Bacillus anthracis
60 days from the confirmation of Bacillus anthracis exposure
Kreatininclearance [ml/ min / 1, 73 m²]
Creatinine Clearance [mL/ min/ 1.73 m²]
124 til 168
124 to 168
62 Rejsediaré Ved valget af ciprofloxacin skal der tages hensyn til resistensen over for ciprofloxacin hos relevante patogener i de lande, der besøges.
61 Travellers’ diarrhoea The choice of ciprofloxacin should take into account information on resistance to ciprofloxacin in relevant pathogens in the countries visited.
63 Allerede 48 timer efter start af behandlingen med ciprofloxacin kan der forekomme tendinitis og seneruptur (specielt af akillessenen), af og til bilateralt.
62 Tendinitis and tendon rupture (especially Achilles tendon), sometimes bilateral, may occur with ciprofloxacin, as soon as the first 48 hours of treatment.
64 Cytokrom P450 Ciprofloxacin hæmmer CYP1A2 og kan derfor medføre øgede serumkoncentrationer af lægemidler, som gives samtidigt, og som metaboliseres af dette enzym (f. eks. teofyllin, clozapin, ropinirol og tizanidin).
63 Cytochrome P450 Ciprofloxacin inhibits CYP1A2 and thus may cause increased serum concentration of concomitantly administered substances metabolised by this enzyme (e. g. theophylline, clozapine, ropinirole, tizanidine).
65 Methotrexat
Methotrexate
Teofyllin
64 Theophylline
66 Amning Ciprofloxacin udskilles i modermælk.
Lactation Ciprofloxacin is excreted in breast milk.
Virkning på evnen til at føre motorkøretøj eller betjene maskiner
65 4.7 Effects on ability to drive and use machines
Organklasse
66 System Organ
beregnes fra de foreliggende data)
Nervous System Disorders
Organklasse
67 System Organ
beregnes fra de foreliggende data) (potentielt livstruende) Knogler, led, muskler og bindevæv
Petechiae Erythema multiforme Erythema nodosum Stevens- Johnson syndrome (potentially life- threatening) Toxic epidermal necrolysis (potentially life- threatening)
Det er indberettet, at en overdosis på 12 g har medført lette toksiske symptomer.
68 An overdose of 12 g has been reported to lead to mild symptoms of toxicity.
S ≤ 0, 5 mg/ l S ≤ 0, 5 mg/ l S ≤ 1 mg/ l
S ≤ 0.5 mg/ L S ≤ 0.5 mg/ L S ≤ 1 mg/ L S ≤ 1 mg/ L
R > 1 mg/ l
69
De skal kun bruges for arter, som
1 Staphylococcus spp. - breakpoints for ciprofloxacin relate to high dose therapy. * Non-species-related breakpoints have been determined mainly on the basis of PK/ PD data and are independent of MIC distributions of specific species.
70 ikke har fået et arts- specifikt breakpoint, og ikke for de arter, hvor testning af følsomhed ikke anbefales.
They are for use only for species that have not been given a species-specific breakpoint and not for those species where susceptibility testing is not recommended.
4. 4 vedrørende Streptokokarter).
Groupings of relevant species according to ciprofloxacin susceptibility (for Streptococcus species see section 4.4)
ALMINDELIGE FØLSOMME ARTER Aerobe grampositive mikroorganismer Bacillus anthracis (1) Aerobe gramnegative mikroorganismer Aeromonas spp.
70 COMMONLY SUSCEPTIBLE SPECIES Aerobic Gram-positive micro-organisms Bacillus anthracis (1) Aerobic Gram-negative micro-organisms Aeromonas spp.
Yersinia pestis Anaerobe mikroorganismer Mobiluncus Andre mikroorganismer Chlamydia trachomatis ($) Chlamydia pneumoniae ($) Mycoplasma hominis ($) Mycoplasma pneumoniae ($) ARTER, HVOR ERHVERVET RESISTENS KAN VÆRE ET PROBLEM Aerobe grampositive mikroorganismer Enterococcus faecalis ($) Staphylococcus spp. * (2) Aerobe gramnegative mikroorganismer Acinetobacter baumannii+ Burkholderia cepacia+ * Campylobacter spp. + * Citrobacter freundii * Enterobacter aerogenes Enterobacter cloacae * Escherichia coli * Klebsiella oxytoca Klebsiella pneumoniae * Morganella morganii * Neisseria gonorrhoeae * Proteus mirabilis * Proteus vulgaris * Providencia spp.
Yersinia pestis Anaerobic micro-organisms Mobiluncus Other micro-organisms Chlamydia trachomatis ($) Chlamydia pneumoniae ($) Mycoplasma hominis ($) Mycoplasma pneumoniae ($) SPECIES FOR WHICH ACQUIRED RESISTANCE MAY BE A PROBLEM Aerobic Gram-positive micro-organisms Enterococcus faecalis ($) Staphylococcus spp. * (2) Aerobic Gram-negative micro-organisms Acinetobacter baumannii+ Burkholderia cepacia+* Campylobacter spp. +* Citrobacter freundii* Enterobacter aerogenes Enterobacter cloacae* Escherichia coli* Klebsiella oxytoca Klebsiella pneumoniae* Morganella morganii* Neisseria gonorrhoeae* Proteus mirabilis* Proteus vulgaris* Providencia spp.
Propionibacterium acnes ORGANISMER MED NATURLIG RESISTENS Aerobe grampositive mikroorganismer Actinomyces
Propionibacterium acnes INHERENTLY RESISTANT ORGANISMS Aerobic Gram-positive micro-organisms Actinomyces Enteroccus faecium Listeria monocytogenes
72 Enteroccus faecium Listeria monocytogenes Aerobe gramnegative mikroorganismer Stenotrophomonas maltophilia Anaerobe mikroorganismer Undtagen ovennævnte Andre mikroorganismer Mycoplasma genitalium Ureaplasma urealitycum * Der er dokumenteret klinisk effekt for følsomme isolater ved godkendte indikationer + Resistensgrad ≥ 50% i et eller flere EU- lande ($):
71 Aerobic Gram-negative micro-organisms Stenotrophomonas maltophilia Anaerobic micro-organisms Excepted as listed above Other micro-organisms Mycoplasma genitalium Ureaplasma urealitycum * Clinical efficacy has been demonstrated for susceptible isolates in approved clinical indications + Resistance rate ≥ 50% in one or more EU countries ($):
73 Ciprofloxacin er kendt for at være en moderat hæmmer af CYP 450 1A2- iso- enzymer.
Ciprofloxacin is known to be a moderate inhibitor of the CYP 450 1A2 iso-enzymes.
Ciprofloxacin udskilles overvejende uændret, både renalt og i mindre grad fækalt.
72 Ciprofloxacin is largely excreted unchanged both renally and, to a smaller extent, faecally.
6. 2 Uforligeligheder
73 6.2 Incompatibilities
Ciprofloxacin Bayer og tilhørende navne (se bilag I) 750 mg filmovertrukne tabletter [Se bilag I – Udfyldes nationalt]
Ciprofloxacin Bayer and associated names (see Annex I) 750 mg film-coated tablets [See Annex I - To be completed nationally]
4. 4 og 5. 1).
Ciprofloxacin Bayer 750 mg film-coated tablets are indicated for the treatment of the following infections (see sections 4.4 and 5.1).
76 • Infektioner i hud og bløddele forårsaget af gramnegative bakterier
• Infections of the skin and soft tissue caused by Gram-negative bacteria
• Malign ekstern otitis
75 • Malignant external otitis
Diaré forårsaget af patogene bakterier, herunder Shigella spp., bortset fra Shigella dysenteriae type 1 og empirisk behandling af svær rejsediaré
Diarrhoea caused by bacterial pathogens including Shigella spp. other than Shigella dysenteriae type 1 and empirical treatment of severe travellers' diarrhoea
Behandlingsvarighed (inklusiv evt. initial parenteral behandling med ciprofloxacin)
1 day (single dose)
Profylakse ved invasive infektioner, som skyldes Neisseria meningitidis
77
500 mg som éngangsdosis
Indications
80 Rejsediaré Ved valget af ciprofloxacin skal der tages hensyn til resistensen over for ciprofloxacin hos relevante patogener i de lande, der besøges.
79 Travellers’ diarrhoea The choice of ciprofloxacin should take into account information on resistance to ciprofloxacin in relevant pathogens in the countries visited.
81 Allerede 48 timer efter start af behandlingen med ciprofloxacin kan der forekomme tendinitis og seneruptur (specielt af akillessenen), af og til bilateralt.
80 Tendinitis and tendon rupture (especially Achilles tendon), sometimes bilateral, may occur with ciprofloxacin, as soon as the first 48 hours of treatment.
82 Cytokrom P450 Ciprofloxacin hæmmer CYP1A2 og kan derfor medføre øgede serumkoncentrationer af lægemidler, som gives samtidigt, og som metaboliseres af dette enzym (f. eks. teofyllin, clozapin, ropinirol og tizanidin).
81 Cytochrome P450 Ciprofloxacin inhibits CYP1A2 and thus may cause increased serum concentration of concomitantly administered substances metabolised by this enzyme (e. g. theophylline, clozapine, ropinirole, tizanidine).
83 Methotrexat
Methotrexate
Teofyllin
82 Theophylline
Samtidig indgift af ciprofloxacin og warfarin kan forstærke den antikoagulante virkning.
. Simultaneous administration of ciprofloxacin with warfarin may augment its anti-coagulant effects.
84 Amning Ciprofloxacin udskilles i modermælk.
Lactation Ciprofloxacin is excreted in breast milk.
4. 7 Virkning på evnen til at føre motorkøretøj eller betjene maskiner
83 4.7 Effects on ability to drive and use machines
Nedenstående tabel angiver de bivirkninger, der er set ved ciprofloxacin i kliniske studier og under overvågning efter markedsføringen (oral, intravenøs og sekventiel behandling).
ADRs derived from clinical studies and post-marketing surveillance with Ciprofloxacin Bayer (oral, intravenous, and sequential therapy) sorted by categories of frequency are listed below.
Bivirkningerne er sorteret efter hyppighed. Hyppighedsanalysen er baseret på oplysninger fra både oral og intravenøs indgift af ciprofloxacin.
The frequency analysis takes into account data from both oral and intravenous administration of ciprofloxacin.
85 Organklasse
84 System Organ
Organklasse
85 System Organ
Det er indberettet, at en overdosis på 12 g har medført lette toksiske symptomer.
86 An overdose of 12 g has been reported to lead to mild symptoms of toxicity.
87 Det er kun en mindre mængde ciprofloxacin (< 10%), der elimineres ved hæmodialyse eller peritonealdialyse.
Only a small quantity of ciprofloxacin (< 10%) is eliminated by haemodialysis or peritoneal dialysis.
Staphylococcus spp. - breakpoints for ciprofloxacin refererer til højdosisbehandling. * Ikke- artsrelaterede breakpoints er primært blevet bestemt på grundlag af PK/ PD- data, og er uafhængige af fordelingerne af MIC for specifikke arter.
1 Staphylococcus spp. - breakpoints for ciprofloxacin relate to high dose therapy. * Non-species-related breakpoints have been determined mainly on the basis of PK/ PD data and are independent of MIC distributions of specific species.
ALMINDELIGE FØLSOMME ARTER Aerobe grampositive mikroorganismer Bacillus anthracis (1) Aerobe gramnegative mikroorganismer Aeromonas spp.
88 COMMONLY SUSCEPTIBLE SPECIES Aerobic Gram-positive micro-organisms Bacillus anthracis (1) Aerobic Gram-negative micro-organisms Aeromonas spp.
Yersinia pestis Anaerobe mikroorganismer Mobiluncus Andre mikroorganismer Chlamydia trachomatis ($) Chlamydia pneumoniae ($) Mycoplasma hominis ($) Mycoplasma pneumoniae ($) ARTER, HVOR ERHVERVET RESISTENS KAN VÆRE ET PROBLEM Aerobe grampositive mikroorganismer Enterococcus faecalis ($) Staphylococcus spp. * (2) Aerobe gramnegative mikroorganismer Acinetobacter baumannii+ Burkholderia cepacia+ * Campylobacter spp. + * Citrobacter freundii * Enterobacter aerogenes Enterobacter cloacae * Escherichia coli * Klebsiella oxytoca Klebsiella pneumoniae * Morganella morganii * Neisseria gonorrhoeae * Proteus mirabilis * Proteus vulgaris * Providencia spp.
Yersinia pestis Anaerobic micro-organisms Mobiluncus Other micro-organisms Chlamydia trachomatis ($) Chlamydia pneumoniae ($) Mycoplasma hominis ($) Mycoplasma pneumoniae ($) SPECIES FOR WHICH ACQUIRED RESISTANCE MAY BE A PROBLEM Aerobic Gram-positive micro-organisms Enterococcus faecalis ($) Staphylococcus spp. *(2) Aerobic Gram-negative micro-organisms Acinetobacter baumannii+ Burkholderia cepacia+* Campylobacter spp. +* Citrobacter freundii* Enterobacter aerogenes Enterobacter cloacae* Escherichia coli* Klebsiella oxytoca Klebsiella pneumoniae* Morganella morganii* Neisseria gonorrhoeae* Proteus mirabilis* Proteus vulgaris* Providencia spp.
90 Enteroccus faecium Listeria monocytogenes Aerobe gramnegative mikroorganismer Stenotrophomonas maltophilia Anaerobe mikroorganismer Undtagen ovennævnte Andre mikroorganismer Mycoplasma genitalium Ureaplasma urealitycum * Der er dokumenteret klinisk effekt for følsomme isolater ved godkendte indikationer + Resistensgrad ≥ 50% i et eller flere EU- lande ($):
89 Aerobic Gram-negative micro-organisms Stenotrophomonas maltophilia Anaerobic micro-organisms Excepted as listed above Other micro-organisms Mycoplasma genitalium Ureaplasma urealitycum * Clinical efficacy has been demonstrated for susceptible isolates in approved clinical indications + Resistance rate ≥ 50% in one or more EU countries ($):
91 Ciprofloxacin er kendt for at være en moderat hæmmer af CYP 450 1A2- iso- enzymer.
Ciprofloxacin is known to be a moderate inhibitor of the CYP 450 1A2 iso-enzymes.
Ciprofloxacin udskilles overvejende uændret, både renalt og i mindre grad fækalt.
90 Ciprofloxacin is largely excreted unchanged both renally and, to a smaller extent, faecally.
6. 2 Uforligeligheder
91 6.2 Incompatibilities
93 1.
92 1.
Ciprofloxacin Bayer og tilhørende navne (se bilag I) 250 mg oral suspension i enkeltdosisposer [Se bilag I – Udfyldes nationalt]
Ciprofloxacin Bayer and associated names (see Annex I) 250 mg oral suspension in single-dose sachets [See Annex I - To be completed nationally]
[Udfyldes nationalt]
Oral suspension (in single-dose sachets) [To be completed nationally]
4. 4 og 5. 1).
The Ciprofloxacin Bayer 250 mg oral suspension in single-dose sachets are indicated for the treatment of the following infections (see sections 4.4 and 5.1).
Før behandling påbegyndes, skal tilgængelige oplysninger om resistens over for ciprofloxacin nøje studeres
Special attention should be paid to available information on resistance to ciprofloxacin before commencing therapy.
Ved ovennævnte infektioner i genitalkanalen som er mistænkt for eller kendt for at skyldes Neisseria gonorrhoeae, er det særligt vigtigt at indhente oplysninger lokalt om, hvor udbredt resistensen over for ciprofloxacin er, og at bekræfte følsomheden på basis af laboratorieundersøgelser.
• Pelvic inflammatory disease including cases due to Neisseria gonorrhoeae In the above genital tract infections when thought or known to be due to Neisseria gonorrhoeae it is particularly important to obtain local information on the prevalence of resistance to ciprofloxacin and to confirm susceptibility based on laboratory testing.
94 • Intraabdominale infektioner
• Intra-abdominal infections
• Malign ekstern otitis
93 • Malignant external otitis
95 Voksne
Adults
organisme) Kronisk suppurativ otitis media
Chronic suppurative otitis media
2- 4 uger (akut) til 4- 6 uger (kronisk)
2-4 weeks (acute) to 4-6 weeks (chronic)
96 Indikationer
Infections of the skin
Daglig dosis i mg
and soft tissue
Behandling af infektioner eller profylakse over for infektioner hos patienter med neutropeni Ciprofloxacin skal gives sammen med andre antibakterielle stoffer i henhold til officielle retningslinjer.
Treatment of infections or prophylaxis of infections in neutropenic patients Ciprofloxacin should be co-administered with appropriate antibacterial agent(s) in accordance to official guidance.
mg to gange dagligt til 750 mg to gange dagligt
500 mg twice daily to 750 mg twice daily
Behandling skal påbegyndes så hurtigt som muligt efter mistanke om eller bekræftet eksponering.
60 days from the confirmation of Bacillus anthracis exposure
500
95
mg to gange dagligt
Daily dose in mg
60 dage efter bekræftelse af eksponering for Bacillus anthracis
Total duration of treatment (potentially including initial parenteral treatment with ciprofloxacin)
10 mg/ kg op til 15 mg/ kg legemsvægt to gange dagligt, maksimalt 500 mg pr. dosis.
body weight twice daily with a maximum of 500 mg per dose.
til 168
to 168
4. 5).
Ciprofloxacin should not be taken with dairy products (e. g. milk, yoghurt) or mineral-fortified fruit juice (e. g. calcium-fortified orange juice) (see section 4.5).
I svære tilfælde, eller hvis patienten ikke kan indtage oral suspension (f. eks. patienter, som får enteral ernæring), bør behandlingen påbegyndes med intravenøs ciprofloxacin, indtil det er muligt at skifte til oral indgift.
In severe cases or if the patient is unable to take oral suspension (e. g. patients on enteral nutrition), it is recommended to commence therapy with intravenous ciprofloxacin until a switch to oral administration is possible.
Ved sådanne infektioner skal ciprofloxacin gives sammen med andre passende antibakterielle midler.
In such infections ciprofloxacin must be co-administered with other appropriate antibacterial agents.
98 Genitale infektioner Epidymoorchitis og underlivsbetændelse kan være forårsaget af fluoroquinolonresistente Neisseria gonorhoeae.
Genital tract infections Epididymo-orchitis and pelvic inflammatory diseases may be caused by fluoroquinolone-resistant Neisseria gonorrhoeae.
Rejsediaré Ved valget af ciprofloxacin skal der tages hensyn til resistensen over for ciprofloxacin hos relevante patogener i de lande, der besøges.
97 The choice of ciprofloxacin should take into account information on resistance to ciprofloxacin in relevant pathogens in the countries visited.
Behandlende læger skal henholde sig til national og/ eller international konsensusdokumentation om behandling af anthrax.
Treating physicians should refer to national and / or international consensus documents regarding the treatment of anthrax.
Allerede 48 timer efter start af behandlingen med ciprofloxacin kan der forekomme tendinitis og seneruptur (specielt af akillessenen), af og til bilateralt.
98 Tendinitis and tendon rupture (especially Achilles tendon), sometimes bilateral, may occur with ciprofloxacin, as soon as the first 48 hours of treatment.
100 Glucose- 6- phosphat dehydrogenase- mangel Hos patienter med glucose- 6- phosphat dehydrogenase- mangel er der indberetninger om hæmolytiske reaktioner ved behandling med ciprofloxacin.
Glucose-6-phosphate dehydrogenase deficiency Haemolytic reactions have been reported with ciprofloxacin in patients with glucose-6-phosphate dehydrogenase deficiency.
Cytokrom P450 Ciprofloxacin hæmmer CYP1A2 og kan derfor medføre øgede serumkoncentrationer af lægemidler, som gives samtidigt, og som metaboliseres af dette enzym (f. eks. teofyllin, clozapin, ropinirol og tizanidin).
99 Cytochrome P450 Ciprofloxacin inhibits CYP1A2 and thus may cause increased serum concentration of concomitantly administered substances metabolised by this enzyme (e. g. theophylline, clozapine, ropinirole, tizanidine).
101 Virkningen af ciprofloxacin på andre lægemidler:
Effects of ciprofloxacin on other medicinal products:
Teofyllin
100 Theophylline
Orale antikoagulantia
Oral ant-icoagulants
Der er set et stort antal tilfælde med stigninger i oral antikoagulant- aktivitet hos patienter, som har fået antibakterielle midler, herunder fluoroquinoloner.
There have been many reports of increases in oral anti-coagulant activity in patients receiving antibacterial agents, including fluoroquinolones.
INR skal derfor overvåges hyppigt under og kort efter samtidig indgift af ciprofloxacin og et oralt antikoagulant middel.
It is recommended that the INR should be monitored frequently during and shortly after co-administration of ciprofloxacin with an oral anti-coagulant agent.
Graviditet De oplysninger, der er tilgængelige vedrørende indgift af ciprofloxacin til gravide kvinder tyder ikke på misdannelser eller foetotoksicitet hhv. neonatal toksicitet efter ciprofloxacin.
Pregnancy The data that are available on administration of ciprofloxacin to pregnant women indicates no malformative or feto/ neonatal toxicity of ciprofloxacin.
Amning Ciprofloxacin udskilles i modermælk.
Lactation Ciprofloxacin is excreted in breast milk.
4. 7 Virkning på evnen til at føre motorkøretøj eller betjene maskiner
101 4.7 Effects on ability to drive and use machines
Anafylaktisk reaktion Anafylaktisk shock (livstruende) (se pkt.
Anaphylactic reaction Anaphylactic shock (life- threatening) (see section 4.4) Serum sickness- like reaction
4. 4) Serumsyg -
Metabolism and Nutrition Disorders
103
Anorexia
Organklasse
102 System Organ